ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

ZIRABEV is approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer: In combination with carboplatin and paclitaxel, followed by ZIRABEV alone, for the treatment of patients with advanced (stage III or IV) disease following initial surgery

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous NSCLC in people who have not received chemotherapy for their advanced disease.

ZIRABEV is a tumor-starving anti-angiogenic therapy. ZIRABEV works differently from chemotherapy. For certain types of cancer, ZIRABEV is taken with chemotherapy. Chemotherapy attacks cancer cells. The purpose of ZIRABEV is to help prevent the growth of new blood vessels that feed the tumor. How does ZIRABEV work?

ZIRABEV está aprobado para tratar el cáncer epitelial de ovario, trompa de Falopio o peritoneo primario: • En combinación con carboplatino y paclitaxel, seguido por ZIRABEV solo, para el tratamiento de pacientes con enfermedad avanzada (estadio III …